+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Agenus Inc (AGEN) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 53 Pages
  • September 2024
  • GlobalData
  • Agenus Inc
  • ID: 1290958
Agenus Inc (AGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Agenus Inc (Agenus) is a biotechnology company. It is advancing therapies targeting cancer through a pipeline of immunological agents. The company's portfolio includes several advanced platforms and programs designed to drive innovation in immuno-oncology (I-O). These consist of multiple proprietary antibody discovery platforms; antibody candidate programs such as botensilimab and balstilimab; a saponin-based vaccine adjuvant platform centered around the STIMULON cultured plant cell (CPC) QS-21 adjuvant and a pipeline of novel allogeneic invariant natural killer T (iNKT) cell therapies for treating cancer and other immune-mediated diseases. Agenus is headquartered in Lexington, Massachusetts, the US.

Agenus Inc Key Recent Developments

  • Sep 03, 2024: Agenus to Participate in September Investor Conferences
  • Aug 08, 2024: Agenus Announces Appointment of Tom Harrison to Board of Directors
  • Jun 17, 2024: Agenus Announces Appointment of Dr. Jennifer Buell to its Board of Directors
  • Oct 26, 2023: Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Agenus Inc - Key Facts
  • Agenus Inc - Key Employees
  • Agenus Inc - Key Employee Biographies
  • Agenus Inc - Major Products and Services
  • Agenus Inc - History
  • Agenus Inc - Company Statement
  • Agenus Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Agenus Inc - Business Description
  • Geographical Segment: Rest Of World
  • Performance
  • Geographical Segment: United States
  • Performance
  • R&D Overview
  • Agenus Inc - Corporate Strategy
  • Agenus Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Agenus Inc - Strengths
  • Agenus Inc - Weaknesses
  • Agenus Inc - Opportunities
  • Agenus Inc - Threats
  • Agenus Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Agenus Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Agenus Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Sep 03, 2024: Agenus to Participate in September Investor Conferences
  • Aug 08, 2024: Agenus Announces Appointment of Tom Harrison to Board of Directors
  • Jun 17, 2024: Agenus Announces Appointment of Dr. Jennifer Buell to its Board of Directors
  • Oct 26, 2023: Agenus to Provide Third Quarter 2023 Financial Report and Corporate Update
  • Jul 20, 2023: Agenus Expands Executive Leadership Team
  • May 09, 2023: Agenus Provides Corporate Update and First Quarter 2023 Financial Results
  • Mar 14, 2023: Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives
  • Mar 11, 2023: Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
  • Feb 28, 2023: Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Agenus Inc, Key Facts
  • Agenus Inc, Key Employees
  • Agenus Inc, Key Employee Biographies
  • Agenus Inc, Major Products and Services
  • Agenus Inc, History
  • Agenus Inc, Subsidiaries
  • Agenus Inc, Key Competitors
  • Agenus Inc, Ratios based on current share price
  • Agenus Inc, Annual Ratios
  • Agenus Inc, Interim Ratios
  • Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Agenus Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Agenus Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Agenus Inc, Performance Chart (2019 - 2023)
  • Agenus Inc, Ratio Charts
  • Agenus Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Agenus Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Genor BioPharma Co Ltd
  • Janssen Pharmaceuticals Inc
  • Dynavax Technologies Corp
  • Amgen Inc
  • CSPC ZhongQi Pharmaceutical Technology Co Ltd
  • Boehringer Ingelheim International GmbH
  • Arcus Biosciences Inc
  • Maxinovel Pharmaceuticals
  • Biocad
  • Qilu Pharmaceutical Co Ltd
  • AbbVie Inc
  • 3D Medicines Inc
  • Novartis AG
  • MacroGenics Inc
  • Incyte Corp
  • Checkpoint Therapeutics Inc
  • MabSpace Biosciences (Suzhou) Co Ltd
  • ImmuneOncia Therapeutics Inc